Bispecific Antibody Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2015 – 2020) and Forecast (2021 – 2027)

$ PRICE - $ 3,000.00$ 8,900.00

Global Bispecific Antibody Market: By Type (IgG Like Molecule, Non-IgG Like Molecule), By Application (Oncology, Autoimmune Disease and Others), By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global bispecific antibody market was valued at US$ 98\6.3 Mn in 2020 and growing at a CAGR of 34.9% over the forecast period to reach US$ 6,318.2 Mn by 2027 owing to launch of new products in the market in the future years. For instance, there are more than 200 bispecific antibodies products in the clinical trials which will be launched mostly among them in the future years. Increasing investments in research and development of the development of bispecific antibody market products and rising prevalence of cancer. According to WHO, around 9.6 people across the globe are responsible for death due to cancer. Presently only two drugs are approved by the U.S.FDA catumaxomab and blinatumomab. Around 30 bispecific antibodies are expected to be launched in the upcoming years that increases the growth of the market. However, limited number of products available in the market and lack of awareness among the patient population restrains the growth of the market. A bispecific antibody is a synthetic protein made up of fragments from two distinct monoclonal antibodies that can bind to two different types of antigens. The most well-studied application of bispecific antibodies is cancer immunotherapy. The majority of bispecific antibodies are being created to treat various malignancies, with infectious disease, CNS diseases, inflammatory, and autoimmune disorders following closely behind. Bispecific antibodies have a higher binding avidity to targets, can interact with more than one surface antigen, and have more cytotoxic effects than monoclonal therapies.

Bispecific Antibody Market

MARKET SUMMARY
-
34.9%
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 34.9%
  • Largest Market– North-America
  • Fastest Growing Market– Europe

Bispecific Antibody Market

  • This report gives a comprehensive outlook on bispecific antibody across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • This report gives historical, current, and future market sizes (US$ Mn) on the basis of type, application, and region.
  • This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
  • Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global bispecific antibody products.
Market Key Players
  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
Growth

Bispecific Antibody Market

A number of pharmaceutical companies are actively involved in research and development of the bispecific antibodies. To launch the products to strengthen their position in the market and expand their product portfolio to offer better services to their patients. Manufacturers are also following various strategies to speed the development process for immediate launch of the products as soon as possible. For instance, In Dec 2016, MedImmune, LLC and Abpro, collaborated to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor.


North-America Got Significant Share

Bispecific Antibody Market

North America is leading the global market and is expected to grow with significant CAGR owing to presence of large number of market players involved in the research and development of new products in the category and rising prevalence of cancer coupled with growing mortality rate in the region is anticipated to drive the growth of the market. Moreover, availability of flexible reimbursement policies in the region is the major factor that drives the growth of the market. Europe is projected to grow with significant CAGR over the forecast years owing to increasing funding from the government for the development of bispecific antibodies and availability of favorable reimbursement for the products.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Findings of the Report

  • Global bispecific antibody market expanding at significant CAGR over 2021 to 2027 owing to number of bispecific antibodies in clinical trials and increasing investments by the market players.
  • Based on region, North America accounted for larger market revenue share in 2020 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global market

Key

Key Features of the Report

Bispecific Antibody Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • NovImmune
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi

Description

The global bispecific antibody market was valued at US$ 98\6.3 Mn in 2020 and growing at a CAGR of 34.9% over the forecast period to reach US$ 6,318.2 Mn by 2027 owing to launch of new products in the market in the future years. For instance, there are more than 200 bispecific antibodies products in the clinical trials which will be launched mostly among them in the future years. Increasing investments in research and development of the development of bispecific antibody market products and rising prevalence of cancer. According to WHO, around 9.6 people across the globe are responsible for death due to cancer. Presently only two drugs are approved by the U.S.FDA catumaxomab and blinatumomab. Around 30 bispecific antibodies are expected to be launched in the upcoming years that increases the growth of the market. However, limited number of products available in the market and lack of awareness among the patient population restrains the growth of the market. A bispecific antibody is a synthetic protein made up of fragments from two distinct monoclonal antibodies that can bind to two different types of antigens. The most well-studied application of bispecific antibodies is cancer immunotherapy. The majority of bispecific antibodies are being created to treat various malignancies, with infectious disease, CNS diseases, inflammatory, and autoimmune disorders following closely behind. Bispecific antibodies have a higher binding avidity to targets, can interact with more than one surface antigen, and have more cytotoxic effects than monoclonal therapies.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX